Clinical Trial Results:
            A phase II, double-blind study to evaluate the safety, reactogenicity and  immunogenicity of two different formulations of GSK Biologicals’ pneumococcal protein candidate vaccine, when given as a booster dose in healthy young adults previously vaccinated in the primary vaccination study SPNG-001 (111651).
    
    Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines
|     Summary | |
|     EudraCT number | 2009-011022-33 | 
|     Trial protocol | BE | 
|     Global completion date | 
                                    05 Aug 2009
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    24 Aug 2016
                             | 
|     First version publication date | 
                                    24 Aug 2016
                             | 
|     Other versions | |
|     Summary report(s) | 112993-Clinical-Study-Result-Summary | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
